StageSeries D | Alive
Last Raised$304M | 2 yrs ago
Medable operates as a global platform for decentralized clinical trials. It solves the systemic challenges inherent in modern clinical trials including access, interoperability between systems, and inefficient technology experiences. It was formerly known as Dermatrap. It was founded in 2012 and is based in Palo Alto, California.
ESPs containing Medable
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The decentralized clinical trials market focuses on conducting clinical research that leverages digital technology to reduce the burden on patients and streamline the trial process. This market offers various solutions that allow for remote participation in clinical trials, including telemedicine, mobile health applications, and wearable devices. By removing the need for frequent visits to clinica…
Medable named as Leader among 15 other companies, including Huma, Curebase, and THREAD.
Compete with Medable?
Ensure that your company and products are accurately represented on our platform.
Medable's Products & Differentiators
To create a seamless experience for site and patients, all of our products are integrated into a single platform. The core Platform contains portals for the site, patient, and sponsor in both web and mobile modalities.
Research containing Medable
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Medable in 10 CB Insights research briefs, most recently on Jul 18, 2022.
Dec 8, 2021 reportThe Digital Health 150: The Top Digital Health Companies Of 2021
Expert Collections containing Medable
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Medable is included in 9 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
Technology that addresses regulatory challenges and facilitates the delivery of compliance requirements in FIs. Regulatory technology helps FIs and regulators address challenges ranging from traditional compliance and risk management to data reporting and transmission.
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
Digital Health 150
The winners of the second annual CB Insights Digital Health 150.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Medable has filed 5 patents.
The 3 most popular patent topics include:
- Health informatics
- Healthcare occupations
- Medical terminology
Data management, Health informatics, Java device platform, Medical terminology, Healthcare occupations
Data management, Health informatics, Java device platform, Medical terminology, Healthcare occupations
Latest Medable News
May 31, 2023
Pamela Tenaerts, chief scientific officer at Medable, is on a mission to democratize and diversify clinical trials. It is no secret that clinical trials play a crucial role in determining the safety and effectiveness of new medical treatments, Tenaerts tells Outsourcing-Pharma. However, she says they have long been plagued by inefficiency, high costs, poor patient retention and lack of diversity, among other issues. In fact, the National Institute of Health estimates that 85% of all clinical trials experience significant operational delays, with 94% being delayed by over a month. Medable is aiming to make the process less cumbersome, using its decentralized clinical trial (DCT) technology to reshape the way trials are conducted. “My job at Medable is to provide the evidence that decentralized clinical trials work in the way we hope they do. We have seen that technology has the potential to make clinical trials much better and more productive,” Tenaerts says. A member of the Junior National Volleyball team in her native Belgium, despite pressure from her coaches to pursue an athletic career, Tenaerts knew that she wanted to be a doctor from an early age. After medical school, she became a general practitioner in Belgium before seeing an ad from The Catholic University Leuven in collaboration with Duke University for a doctor who could speak multiple languages and wanted to travel. At age 27, Tenaerts accepted the job, where she “fell in love” with clinical research, explaining “I love that you can set up an experiment and establish a methodology to determine if a new treatment works or not. Working in clinical trials is like being an explorer of medicines.” After a stint as executive director of CTTI (Clinical Trials Transformation Initiative), a partnership between Duke University and the FDA, Tenaerts joined Medable in 2021. What does Medable do? Medable’s software-as-a-service (SaaS) platform has been used in more than 300 decentralized and hybrid clinical trials, serving over one million patients and research participants in 60 countries. “Essentially, we are aiming to bring all the different components of clinical trials under one roof,” Tenaerts says. The company’s technology enables remote participation, so patients can take part in trials without needing to travel to a clinic every time they need to be tested. “When you do clinical trials, a lot of people use a lot of vendors. There will be one person that does consenting, another than does clinical outcome assessments and all the information is separate. However, when you use a technology like Medable, all the data is streamlined through one system and it's only one vendor you're dealing with,” Tenaerts says. The technology can collect a diverse range of study data – including patient reported outcomes, smartphone sensor data, contextual data sets (UV index, urban air pollution, location), and medical and wearable device data. Medable has partnered with several pharma industry giants, with GlaxoSmithKline (GSK) recently selecting its DCT platform to use across its portfolio, indicating a wider industry shift towards hybrid and decentralized trial models. In addition, this month the US Food and Drug Administration (FDA) released new guidance in favour of DCT’s to “provide clarity” on the agency’s support for these “innovative trial measures”. “The new guidance has taken DCT’s to another level of validation, by having the backing of such an important body in the US and around the world saying that we support DCT’s as an effective mechanism to conduct trials,” Tenaerts says. How is it improving the clinical trial landscape? According to Tenaerts, Medable’s DCT technology can not only collect more accurate and nuanced medical information, but also improve diversity and inclusivity among participants. In a traditional clinical trial, patients would come into a centre every month to do a standard assessment, such as the 6-min walk test (6MWT) to determine if their condition is improving or declining. The 6MWT is a commonly used metric of walking capacity in people with Parkinson’s disease. “However, Parkinson’s is typified by having good days and bad days. So if one month you come into the clinic on a good day and the next month on a bad day, it doesn’t give us a comprehensive overview of how that patient is doing,” Tenaerts says. “Whereas if you were to use a Fitbit, or something that you measured every day, you have more continuous data which may be better and give you more information about how that patient is doing.” Technology can also enable companies to collect patient data faster, which can be crucial when large amounts of money are on the line. “For sponsors of clinical trials, if they have a product which they think will help a lot of people, it’s vital to get that product on the market as soon as possible,” Tenaerts adds. “To be able to do that, you have to have a clinical trial that ends and you need to have positive data to show that your product works. “If you have a blockbuster drug on your hand, its millions of dollars a day. It’s important to get the treatment out there, for customers and also for sponsors – so they can get return on investment.” While Tenaerts acknowledges that investing in technology can make your trial more expensive, she cites research from Medable and Tufts University showing that, on average, companies who make the investment can end their trial 3 months earlier – which can save significant amounts of money. Tackling the diversity issue The expectation that patients must travel to a centralized site to take part in clinical trials has resulted in a severe lack of diversity. However, Tenaerts argues that decentralization mitigates geographical and socio-economic barriers, to reach a larger and more diverse pool of patients. “DTC’s can remove geography as a barrier. But while geography as a barrier is distance, sometimes it can be modes of transportation,” Tenaerts says. “If you are in a lower economic group, you may not have extra money to take a bus to the site, let alone the time to participate and maybe you don’t have anyone to watch your kids. So the convenience factor for patients is extremely important.” Tenaerts explains that she ran a trial site in Florida for 12 years, but most of the people able to participate were older, white males who were retired and therefore had ample time and resources to visit. “Historically, the industry has not been good at enrolling the people in the trial that look like the people who have the condition you're studying. If a disease is particularly prevalent among minorities, its important that we provide a mechanism for everyone participate and that we make that possible,” she says. “If you only study something in Caucasian people or people from a higher socio-economic background, the medication may work in different ways. This doesn’t always have to do with how the medication itself works, but how these patients live and the social determinants of health. “For instance, if people live in food deserts, if they can’t make healthy choices, whether that’s exercising or food of if they can’t see their doctors regularly – that changes how well or badly a drug can work.” What still needs to be done? Despite hailing the benefits of Medable’s DTC technology, Tenaerts admits that there are still wider societal barriers to overcome. “It’s about being thoughtful and honest. There are still many areas in the US that don’t have access to Wi-Fi in the way that they should,” she says. In fact, the Federal Communications Commission found that approximately 19 million Americans, 6% of the population, still lack access to fixed broadband service at threshold speeds. In rural areas, nearly one-fourth of the population, 14.5 million people, lack access to this service, rising to one-third of the population in tribal areas. One institution attempting to tackle this issue is the US Veterans Health Administration. When the organisation started conducting televisits, it found many veterans could not participate due to a lack of internet connection, Tenaerts explains. In response, they set up a contract with Walmart, enabling veterans to use the retail giant’s Wi-Fi and computers so they could participate in trials and input their health data. “Therefore, we need to think about different models and facilitating services where patients are excluded due to circumstance,” Tenaerts says. As clinical trials are a central part of discovering and developing new medicines, the landscape will continue to evolve, with individuals like Tenaerts championing technological and structural innovations. “In the end, if applied thoughtfully – all these technologies have the ability to make clinical trials much better,” she says. “For this technology to be widespread, a lot of things need to happen but its good we’re at the forefront. We will keep pushing and adapting to the ever-changing requirements of patients and industry.” Copyright - Unless otherwise stated all contents of this web site are © 2023 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Medable Frequently Asked Questions (FAQ)
When was Medable founded?
Medable was founded in 2012.
Where is Medable's headquarters?
Medable's headquarters is located at 525 University Avenue, Palo Alto.
What is Medable's latest funding round?
Medable's latest funding round is Series D.
How much did Medable raise?
Medable raised a total of $533.75M.
Who are the investors of Medable?
Investors of Medable include GSR Ventures, Sapphire Ventures, Tiger Global Management, Blackstone, Western Technology Investment and 10 more.
Who are Medable's competitors?
Competitors of Medable include Lindus Health, Alira Health, JNPMEDI, Medocity, Jeeva, WKD.SMRT, Delve Health, Curebase, Huma, Clara Health and 21 more.
What products does Medable offer?
Medable's products include Medable Platform and 2 more.
Who are Medable's customers?
Customers of Medable include GSK and Syneos.
Compare Medable to Competitors
Curebase provides decentralized clinical research software solutions. It reduces recruitment times, automates manual steps, and lets drug companies distribute their trials to clinics. It was founded in 2017 and is based in San Francisco, California.
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
Reify Health provides cloud-based software that accelerates the development of new and life-saving therapies. Reify Health aims to change how clinical trials are run through its StudyTeam and Care Access platforms. StudyTeam delivers a technology platform for optimizing patient recruitment and enrollment. Care Access, which conducts decentralized trials at scale, is a decentralized research organization that aims to bring clinical trial infrastructure directly to patients, healthcare providers, and communities. Reify Health was founded in 2012 and is based in Boston, Massachusetts.
Castor EDC is a medical research data platform. It provides a decentralized clinical trial (DCT) solutions to control clinical trial design. It analyzes, manages, and organizes medical data collected from multiple electronic records. the company was founded in 2011 and is based in New York, New York.
Evidation operates as a multichannel health tracking platform. It enables users to connect with multiple appications to track everyday activity and earn rewards for steps, sleep, surveys, and more. The company was founded in 2012 and is based in San Mateo, California.
Saama Technologies is a clinical data and analytics company. Saama's unified, AI-driven clinical data analytics platform integrates, curates, and animates unlimited sources of structured, unstructured, and real-world data to deliver insights across all therapeutic areas. The platform gives real-time visibility into clinical data, enabling sponsors to file New Drug Applications (NDAs) more efficiently to bring drugs to market faster and at lower costs. Saama Technologies was founded in 1997 and is based in Campbell, California.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.